Vaccination of Dendritic Cells Loaded with Interleukin-12-Secreting Cancer Cells Augments In vivo Antitumor Immunity: Characteristics of Syngeneic and Allogeneic Antigen-Presenting Cell Cancer Hybrid Cells
Cancer immunotherapy by fusion of antigen-presenting cells and tumor cells has been shown to induce potent antitumor immunity. In this study, we characterized syngeneic and allogeneic, murine macrophage/dendritic cell (DC)-cancer fusion cells for the antitumor effects. The results showed the superio...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2005-01, Vol.11 (1), p.58-66 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 66 |
|---|---|
| container_issue | 1 |
| container_start_page | 58 |
| container_title | Clinical cancer research |
| container_volume | 11 |
| creator | SUZUKI, Takuji FUKUHARA, Tatsuro HAGIWARA, Koichi SAIJO, Yasuo NUKIWA, Toshihiro TANAKA, Masashi NAKAMURA, Akira AKIYAMA, Kenichi SAKAKIBARA, Tomohiro KOINUMA, Daizo KIKUCHI, Toshiaki TAZAWA, Ryushi MAEMONDO, Makoto |
| description | Cancer immunotherapy by fusion of antigen-presenting cells and tumor cells has been shown to induce potent antitumor immunity.
In this study, we characterized syngeneic and allogeneic, murine macrophage/dendritic cell (DC)-cancer fusion cells for the
antitumor effects. The results showed the superiority of allogeneic cells as fusion partners in both types of antigen-presenting
cells in an in vivo immunotherapy model. A potent induction of tumor-specific CTLs was observed in these immunized conditions. In addition, the
immunization with DC-cancer fusion cells was better than that with macrophage-cancer fusion cells. Both syngeneic and allogeneic
DC-cancer fusion cells induced higher levels of IFN-γ production than macrophage-cancer fusion cells. Interestingly, allogeneic
DC-cancer fusion cells were superior in that they efficiently induced Th1-type cytokines but not the Th2-type cytokines interleukin
(IL)-10 and IL-4, whereas syngeneic DC-cancer fusion cells were powerful inducers of both Th1 and Th2 cytokines. These results
suggest that allogeneic DCs are suitable as fusion cells in cancer immunotherapy. To further enhance the antitumor immunity
in the clinical setting, we prepared DCs fused with IL-12 gene-transferred cancer cells and thus generated IL-12-secreting DC-cancer fusion cells. Immunization with these gene-modified
DC-cancer fusion cells was able to elicit a markedly enhanced antitumor effect in the in vivo therapeutic model. This novel IL-12-producing fusion cell vaccine might be one promising intervention for future cancer immunotherapy. |
| doi_str_mv | 10.1158/1078-0432.58.11.1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67386631</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67386631</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-1f2c1028362f8f513ae3fc89d0219ed6e621b8bbd4e46539f98f57d8bdbc4b963</originalsourceid><addsrcrecordid>eNqFkc-O0zAQxiMEYv_AA3BBvsAtxRMnjsOtCixbqRJIC1wjx560hsRZbGdXfUjeCafNqkdOHtvffL_RfEnyBugKoBAfgJYipTnLVoWILyt4llxCUZQpy3jxPNZP_xfJlfe_KIUcaP4yuYCCl1Bk4jL5-1MqZawMZrRk7MgntNqZYBSpse892Y5SoyaPJuzJxgZ0PU6_jU0hS-9QOQzG7kgtrUK3dKyn3YA2-CgnD-ZhJGsbTJiG0ZHNMEzWhMNHUu-lkyraGR9ZfibfHewOLUaytJqs-35crnN_LNNvDn00PgIj6Yl6e2id0Sf4q-RFJ3uPr5fzOvlx8_l7fZtuv37Z1OttqnKWhxS6TAHNBONZJ7oCmETWKVFpmkGFmiPPoBVtq3PMecGqroqqUotWtypvK86uk_cn33s3_pnQh2YwXsUJpMVx8g0vmeCcwX-FUJVZKSiNQjgJlRu9d9g1984M0h0aoM0cdjOH2cxhNvMFmtn87WI-tQPqc8eSbhS8WwTSK9l3Lm7M-LOO50yUrDpPuTe7_aNx2KjjbueFS6f2R1zEsn_1NcK2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19727800</pqid></control><display><type>article</type><title>Vaccination of Dendritic Cells Loaded with Interleukin-12-Secreting Cancer Cells Augments In vivo Antitumor Immunity: Characteristics of Syngeneic and Allogeneic Antigen-Presenting Cell Cancer Hybrid Cells</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>American Association for Cancer Research</source><source>Alma/SFX Local Collection</source><creator>SUZUKI, Takuji ; FUKUHARA, Tatsuro ; HAGIWARA, Koichi ; SAIJO, Yasuo ; NUKIWA, Toshihiro ; TANAKA, Masashi ; NAKAMURA, Akira ; AKIYAMA, Kenichi ; SAKAKIBARA, Tomohiro ; KOINUMA, Daizo ; KIKUCHI, Toshiaki ; TAZAWA, Ryushi ; MAEMONDO, Makoto</creator><creatorcontrib>SUZUKI, Takuji ; FUKUHARA, Tatsuro ; HAGIWARA, Koichi ; SAIJO, Yasuo ; NUKIWA, Toshihiro ; TANAKA, Masashi ; NAKAMURA, Akira ; AKIYAMA, Kenichi ; SAKAKIBARA, Tomohiro ; KOINUMA, Daizo ; KIKUCHI, Toshiaki ; TAZAWA, Ryushi ; MAEMONDO, Makoto</creatorcontrib><description>Cancer immunotherapy by fusion of antigen-presenting cells and tumor cells has been shown to induce potent antitumor immunity.
In this study, we characterized syngeneic and allogeneic, murine macrophage/dendritic cell (DC)-cancer fusion cells for the
antitumor effects. The results showed the superiority of allogeneic cells as fusion partners in both types of antigen-presenting
cells in an in vivo immunotherapy model. A potent induction of tumor-specific CTLs was observed in these immunized conditions. In addition, the
immunization with DC-cancer fusion cells was better than that with macrophage-cancer fusion cells. Both syngeneic and allogeneic
DC-cancer fusion cells induced higher levels of IFN-γ production than macrophage-cancer fusion cells. Interestingly, allogeneic
DC-cancer fusion cells were superior in that they efficiently induced Th1-type cytokines but not the Th2-type cytokines interleukin
(IL)-10 and IL-4, whereas syngeneic DC-cancer fusion cells were powerful inducers of both Th1 and Th2 cytokines. These results
suggest that allogeneic DCs are suitable as fusion cells in cancer immunotherapy. To further enhance the antitumor immunity
in the clinical setting, we prepared DCs fused with IL-12 gene-transferred cancer cells and thus generated IL-12-secreting DC-cancer fusion cells. Immunization with these gene-modified
DC-cancer fusion cells was able to elicit a markedly enhanced antitumor effect in the in vivo therapeutic model. This novel IL-12-producing fusion cell vaccine might be one promising intervention for future cancer immunotherapy.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.58.11.1</identifier><identifier>PMID: 15671528</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>allogeneic ; Animals ; Antigen-Presenting Cells - immunology ; Antineoplastic agents ; Antineoplastic Agents - pharmacology ; Biological and medical sciences ; cancer immunotherapy ; Cancer Vaccines ; Cell Line, Tumor ; Dendritic Cells - cytology ; Female ; fusion cell ; Hybrid Cells ; IL-12 ; Immunotherapy - methods ; Interferon-gamma - metabolism ; Interleukin-10 - metabolism ; Interleukin-12 - genetics ; Interleukin-12 - metabolism ; Interleukin-4 - metabolism ; Macrophages - metabolism ; Medical sciences ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Neoplasm Transplantation ; Neoplasms - drug therapy ; Neoplasms - immunology ; Neoplasms - metabolism ; Pharmacology. Drug treatments ; Spleen - cytology ; T-Lymphocytes - metabolism ; Time Factors</subject><ispartof>Clinical cancer research, 2005-01, Vol.11 (1), p.58-66</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-1f2c1028362f8f513ae3fc89d0219ed6e621b8bbd4e46539f98f57d8bdbc4b963</citedby><cites>FETCH-LOGICAL-c434t-1f2c1028362f8f513ae3fc89d0219ed6e621b8bbd4e46539f98f57d8bdbc4b963</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,3357,4025,27928,27929,27930</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16438739$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15671528$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SUZUKI, Takuji</creatorcontrib><creatorcontrib>FUKUHARA, Tatsuro</creatorcontrib><creatorcontrib>HAGIWARA, Koichi</creatorcontrib><creatorcontrib>SAIJO, Yasuo</creatorcontrib><creatorcontrib>NUKIWA, Toshihiro</creatorcontrib><creatorcontrib>TANAKA, Masashi</creatorcontrib><creatorcontrib>NAKAMURA, Akira</creatorcontrib><creatorcontrib>AKIYAMA, Kenichi</creatorcontrib><creatorcontrib>SAKAKIBARA, Tomohiro</creatorcontrib><creatorcontrib>KOINUMA, Daizo</creatorcontrib><creatorcontrib>KIKUCHI, Toshiaki</creatorcontrib><creatorcontrib>TAZAWA, Ryushi</creatorcontrib><creatorcontrib>MAEMONDO, Makoto</creatorcontrib><title>Vaccination of Dendritic Cells Loaded with Interleukin-12-Secreting Cancer Cells Augments In vivo Antitumor Immunity: Characteristics of Syngeneic and Allogeneic Antigen-Presenting Cell Cancer Hybrid Cells</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Cancer immunotherapy by fusion of antigen-presenting cells and tumor cells has been shown to induce potent antitumor immunity.
In this study, we characterized syngeneic and allogeneic, murine macrophage/dendritic cell (DC)-cancer fusion cells for the
antitumor effects. The results showed the superiority of allogeneic cells as fusion partners in both types of antigen-presenting
cells in an in vivo immunotherapy model. A potent induction of tumor-specific CTLs was observed in these immunized conditions. In addition, the
immunization with DC-cancer fusion cells was better than that with macrophage-cancer fusion cells. Both syngeneic and allogeneic
DC-cancer fusion cells induced higher levels of IFN-γ production than macrophage-cancer fusion cells. Interestingly, allogeneic
DC-cancer fusion cells were superior in that they efficiently induced Th1-type cytokines but not the Th2-type cytokines interleukin
(IL)-10 and IL-4, whereas syngeneic DC-cancer fusion cells were powerful inducers of both Th1 and Th2 cytokines. These results
suggest that allogeneic DCs are suitable as fusion cells in cancer immunotherapy. To further enhance the antitumor immunity
in the clinical setting, we prepared DCs fused with IL-12 gene-transferred cancer cells and thus generated IL-12-secreting DC-cancer fusion cells. Immunization with these gene-modified
DC-cancer fusion cells was able to elicit a markedly enhanced antitumor effect in the in vivo therapeutic model. This novel IL-12-producing fusion cell vaccine might be one promising intervention for future cancer immunotherapy.</description><subject>allogeneic</subject><subject>Animals</subject><subject>Antigen-Presenting Cells - immunology</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>cancer immunotherapy</subject><subject>Cancer Vaccines</subject><subject>Cell Line, Tumor</subject><subject>Dendritic Cells - cytology</subject><subject>Female</subject><subject>fusion cell</subject><subject>Hybrid Cells</subject><subject>IL-12</subject><subject>Immunotherapy - methods</subject><subject>Interferon-gamma - metabolism</subject><subject>Interleukin-10 - metabolism</subject><subject>Interleukin-12 - genetics</subject><subject>Interleukin-12 - metabolism</subject><subject>Interleukin-4 - metabolism</subject><subject>Macrophages - metabolism</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Inbred C57BL</subject><subject>Neoplasm Transplantation</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - metabolism</subject><subject>Pharmacology. Drug treatments</subject><subject>Spleen - cytology</subject><subject>T-Lymphocytes - metabolism</subject><subject>Time Factors</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc-O0zAQxiMEYv_AA3BBvsAtxRMnjsOtCixbqRJIC1wjx560hsRZbGdXfUjeCafNqkdOHtvffL_RfEnyBugKoBAfgJYipTnLVoWILyt4llxCUZQpy3jxPNZP_xfJlfe_KIUcaP4yuYCCl1Bk4jL5-1MqZawMZrRk7MgntNqZYBSpse892Y5SoyaPJuzJxgZ0PU6_jU0hS-9QOQzG7kgtrUK3dKyn3YA2-CgnD-ZhJGsbTJiG0ZHNMEzWhMNHUu-lkyraGR9ZfibfHewOLUaytJqs-35crnN_LNNvDn00PgIj6Yl6e2id0Sf4q-RFJ3uPr5fzOvlx8_l7fZtuv37Z1OttqnKWhxS6TAHNBONZJ7oCmETWKVFpmkGFmiPPoBVtq3PMecGqroqqUotWtypvK86uk_cn33s3_pnQh2YwXsUJpMVx8g0vmeCcwX-FUJVZKSiNQjgJlRu9d9g1984M0h0aoM0cdjOH2cxhNvMFmtn87WI-tQPqc8eSbhS8WwTSK9l3Lm7M-LOO50yUrDpPuTe7_aNx2KjjbueFS6f2R1zEsn_1NcK2</recordid><startdate>20050101</startdate><enddate>20050101</enddate><creator>SUZUKI, Takuji</creator><creator>FUKUHARA, Tatsuro</creator><creator>HAGIWARA, Koichi</creator><creator>SAIJO, Yasuo</creator><creator>NUKIWA, Toshihiro</creator><creator>TANAKA, Masashi</creator><creator>NAKAMURA, Akira</creator><creator>AKIYAMA, Kenichi</creator><creator>SAKAKIBARA, Tomohiro</creator><creator>KOINUMA, Daizo</creator><creator>KIKUCHI, Toshiaki</creator><creator>TAZAWA, Ryushi</creator><creator>MAEMONDO, Makoto</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20050101</creationdate><title>Vaccination of Dendritic Cells Loaded with Interleukin-12-Secreting Cancer Cells Augments In vivo Antitumor Immunity: Characteristics of Syngeneic and Allogeneic Antigen-Presenting Cell Cancer Hybrid Cells</title><author>SUZUKI, Takuji ; FUKUHARA, Tatsuro ; HAGIWARA, Koichi ; SAIJO, Yasuo ; NUKIWA, Toshihiro ; TANAKA, Masashi ; NAKAMURA, Akira ; AKIYAMA, Kenichi ; SAKAKIBARA, Tomohiro ; KOINUMA, Daizo ; KIKUCHI, Toshiaki ; TAZAWA, Ryushi ; MAEMONDO, Makoto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-1f2c1028362f8f513ae3fc89d0219ed6e621b8bbd4e46539f98f57d8bdbc4b963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>allogeneic</topic><topic>Animals</topic><topic>Antigen-Presenting Cells - immunology</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>cancer immunotherapy</topic><topic>Cancer Vaccines</topic><topic>Cell Line, Tumor</topic><topic>Dendritic Cells - cytology</topic><topic>Female</topic><topic>fusion cell</topic><topic>Hybrid Cells</topic><topic>IL-12</topic><topic>Immunotherapy - methods</topic><topic>Interferon-gamma - metabolism</topic><topic>Interleukin-10 - metabolism</topic><topic>Interleukin-12 - genetics</topic><topic>Interleukin-12 - metabolism</topic><topic>Interleukin-4 - metabolism</topic><topic>Macrophages - metabolism</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Inbred C57BL</topic><topic>Neoplasm Transplantation</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - metabolism</topic><topic>Pharmacology. Drug treatments</topic><topic>Spleen - cytology</topic><topic>T-Lymphocytes - metabolism</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SUZUKI, Takuji</creatorcontrib><creatorcontrib>FUKUHARA, Tatsuro</creatorcontrib><creatorcontrib>HAGIWARA, Koichi</creatorcontrib><creatorcontrib>SAIJO, Yasuo</creatorcontrib><creatorcontrib>NUKIWA, Toshihiro</creatorcontrib><creatorcontrib>TANAKA, Masashi</creatorcontrib><creatorcontrib>NAKAMURA, Akira</creatorcontrib><creatorcontrib>AKIYAMA, Kenichi</creatorcontrib><creatorcontrib>SAKAKIBARA, Tomohiro</creatorcontrib><creatorcontrib>KOINUMA, Daizo</creatorcontrib><creatorcontrib>KIKUCHI, Toshiaki</creatorcontrib><creatorcontrib>TAZAWA, Ryushi</creatorcontrib><creatorcontrib>MAEMONDO, Makoto</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SUZUKI, Takuji</au><au>FUKUHARA, Tatsuro</au><au>HAGIWARA, Koichi</au><au>SAIJO, Yasuo</au><au>NUKIWA, Toshihiro</au><au>TANAKA, Masashi</au><au>NAKAMURA, Akira</au><au>AKIYAMA, Kenichi</au><au>SAKAKIBARA, Tomohiro</au><au>KOINUMA, Daizo</au><au>KIKUCHI, Toshiaki</au><au>TAZAWA, Ryushi</au><au>MAEMONDO, Makoto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vaccination of Dendritic Cells Loaded with Interleukin-12-Secreting Cancer Cells Augments In vivo Antitumor Immunity: Characteristics of Syngeneic and Allogeneic Antigen-Presenting Cell Cancer Hybrid Cells</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2005-01-01</date><risdate>2005</risdate><volume>11</volume><issue>1</issue><spage>58</spage><epage>66</epage><pages>58-66</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Cancer immunotherapy by fusion of antigen-presenting cells and tumor cells has been shown to induce potent antitumor immunity.
In this study, we characterized syngeneic and allogeneic, murine macrophage/dendritic cell (DC)-cancer fusion cells for the
antitumor effects. The results showed the superiority of allogeneic cells as fusion partners in both types of antigen-presenting
cells in an in vivo immunotherapy model. A potent induction of tumor-specific CTLs was observed in these immunized conditions. In addition, the
immunization with DC-cancer fusion cells was better than that with macrophage-cancer fusion cells. Both syngeneic and allogeneic
DC-cancer fusion cells induced higher levels of IFN-γ production than macrophage-cancer fusion cells. Interestingly, allogeneic
DC-cancer fusion cells were superior in that they efficiently induced Th1-type cytokines but not the Th2-type cytokines interleukin
(IL)-10 and IL-4, whereas syngeneic DC-cancer fusion cells were powerful inducers of both Th1 and Th2 cytokines. These results
suggest that allogeneic DCs are suitable as fusion cells in cancer immunotherapy. To further enhance the antitumor immunity
in the clinical setting, we prepared DCs fused with IL-12 gene-transferred cancer cells and thus generated IL-12-secreting DC-cancer fusion cells. Immunization with these gene-modified
DC-cancer fusion cells was able to elicit a markedly enhanced antitumor effect in the in vivo therapeutic model. This novel IL-12-producing fusion cell vaccine might be one promising intervention for future cancer immunotherapy.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>15671528</pmid><doi>10.1158/1078-0432.58.11.1</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2005-01, Vol.11 (1), p.58-66 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67386631 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; American Association for Cancer Research; Alma/SFX Local Collection |
| subjects | allogeneic Animals Antigen-Presenting Cells - immunology Antineoplastic agents Antineoplastic Agents - pharmacology Biological and medical sciences cancer immunotherapy Cancer Vaccines Cell Line, Tumor Dendritic Cells - cytology Female fusion cell Hybrid Cells IL-12 Immunotherapy - methods Interferon-gamma - metabolism Interleukin-10 - metabolism Interleukin-12 - genetics Interleukin-12 - metabolism Interleukin-4 - metabolism Macrophages - metabolism Medical sciences Mice Mice, Inbred BALB C Mice, Inbred C57BL Neoplasm Transplantation Neoplasms - drug therapy Neoplasms - immunology Neoplasms - metabolism Pharmacology. Drug treatments Spleen - cytology T-Lymphocytes - metabolism Time Factors |
| title | Vaccination of Dendritic Cells Loaded with Interleukin-12-Secreting Cancer Cells Augments In vivo Antitumor Immunity: Characteristics of Syngeneic and Allogeneic Antigen-Presenting Cell Cancer Hybrid Cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T13%3A48%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vaccination%20of%20Dendritic%20Cells%20Loaded%20with%20Interleukin-12-Secreting%20Cancer%20Cells%20Augments%20In%20vivo%20Antitumor%20Immunity:%20Characteristics%20of%20Syngeneic%20and%20Allogeneic%20Antigen-Presenting%20Cell%20Cancer%20Hybrid%20Cells&rft.jtitle=Clinical%20cancer%20research&rft.au=SUZUKI,%20Takuji&rft.date=2005-01-01&rft.volume=11&rft.issue=1&rft.spage=58&rft.epage=66&rft.pages=58-66&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.58.11.1&rft_dat=%3Cproquest_cross%3E67386631%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19727800&rft_id=info:pmid/15671528&rfr_iscdi=true |